Por tanto, aunque la información de que disponemos para el manejo de dichas pacientes es aún escasa, los últimos resultados publicados deben llevarnos a ser optimistas en el tratamiento de estas situaciones.

Conflicto de interés
Los autores declaran que no tienen conflictos de interés potenciales relacionados con los contenidos de este artículo.

Tabla 2. Datos analíticos

<table>
<thead>
<tr>
<th>Semanas de gestación</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>16</th>
<th>20</th>
<th>24</th>
<th>28</th>
<th>32</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobina (g/dl)</td>
<td>9,2</td>
<td>9,7</td>
<td>9,8</td>
<td>9,4</td>
<td>8,4</td>
<td>9,8</td>
<td>10,3</td>
<td>9,4</td>
</tr>
<tr>
<td>Hematocrito (%)</td>
<td>27</td>
<td>29,1</td>
<td>30,9</td>
<td>27,0</td>
<td>24,4</td>
<td>29,0</td>
<td>30,1</td>
<td>27,8</td>
</tr>
<tr>
<td>Calcio (mg/dl)</td>
<td>8,2</td>
<td>9,2</td>
<td>9,7</td>
<td>10,1</td>
<td>9,4</td>
<td>9,1</td>
<td>9,9</td>
<td>9,6</td>
</tr>
<tr>
<td>Bicarbonato (mEq/l)</td>
<td>21,8</td>
<td>24,2</td>
<td>25,4</td>
<td>25,0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urea predialisis (mg/dl)</td>
<td>104</td>
<td>109</td>
<td>92</td>
<td>68</td>
<td>63</td>
<td>101</td>
<td>64</td>
<td>96</td>
</tr>
</tbody>
</table>

La prevalencia de C1qN ha sido estimada desde 0.2% a 16%.1-9. Light microscopy (LM) findings range from no glomerular abnormalities to mesangial proliferation10-12 or focal segmental glomerulosclerosis (FSG)1-4,8,1-15. Clinical presentations vary from asymptomatic urinary anomalies1,3-6-13 and macroscopic hematuria14, to nephritic syndrome1-15 and corticosteroid-resistant nephrotic syndrome (NS)1,4,6,16. Earlier reports found a poor response to steroids and a high risk of progression to end-stage renal disease (ESRD)1,4,6,12,15, particularly those with FSG. Patients presenting asymptomatic urinary anomalies have been found to have a good prognosis1-3,7-8. The variability in the prevalence, clinical presentation and prognosis of C1qN has been attributed to different ages and ethnicities of the patients included in the series, and to different thresholds to perform a renal biopsy.

The association between NS and malignancy has been reported in various glomerulopathies, but not with C1qN. Recognition of malignancy-associated glomerulopathies is important to prevent ineffective and potentially harmful treatment.

A 56-year-old male was admitted to our Department with NS. He reported persistent peripheral edema lasting for two months. He was a smoker of 80 packs/year. He had exuberant edema of lower extremities and abdominal wall. Laboratory findings revealed hypoulbuminemia (1.1g/dL), proteinuria (10g/day) and microscopic hematuria; serum creatinine was 1.1mg/dL and urea: 48mg/dL. Hyperlipidemia (total-cholesterol: 326mg/dL) was also noted. HBs-antigen, HCV-antibody and HIV-antibody were all negative. Serum protein electrophoresis was unremarkable; complement levels, ANCA, ANA, cryoglobulins and anti-phospholipid antibodies were normal. Ultrasonography of the kidneys was unremarkable. Abdominal ultrasonography showed small volume ascites, and chest X-ray revealed small pleural effusions, without any other abnormal findings.

Maria Ruiz-Campuzano1, Silvia Soto-Alarcón2, Antonio Martínez-Ruiz1, Eladio Lucas-Guillén1
1 Servicio de Medicina Interna. Hospital Rafael Méndez. Lorca, Murcia.
2 Sección de Nefrología. Hospital Rafael Méndez. Lorca, Murcia.
Correspondencia: Maria Ruiz Campuzano Servicio de Medicina Interna. Hospital Rafael Méndez. Lorca, Murcia. mariaruc@hotmail.com

C1q Nephropathy and Malignancy
Nefrologia 2012;32(2):270-2

Dear Editor,
C1q nephropathy (C1qN) is an idiopathic glomerular disease characterized by extensive mesangial deposition of C1q with associated mesangial immune complexes, in the absence of evidence of systemic lupus erythematosus1.
In an attempt to reduce proteinuria, non-steroidal anti-inflammatory drugs were tried, without response. Cyclosporine was stopped and a right nephrectomy was performed. FSG was noted in all of the 15 glomeruli, with persistence of mesangial C1q deposits. It is plausible that the first biopsy was not representative, or maybe this findings represented the rapid course of the disease.

In the post-operative period, the patient developed signs of hyperhydration and started haemodialysis. Hypoalbuminemia and signs of hyperhydration gradually improved, but he maintained severe proteinuria. When clinical euvolemia was achieved, a right pleural effusion persisted. A CT scan was performed, revealing a disseminated neoplasm (Figure 2). A pleural exudate without malignant cells was drained. Tumor markers Ca19.9 (95.2U/L, normal <27U/L) and neuron specific enolase (NSE) (96.6U/L, normal <15.2U/L) were elevated.

The patient’s general condition rapidly deteriorated with marked cachexy and, later on, respiratory failure. Invasive investigation was not possible, as the patient was not fit. A week later, he died with a nosocomial respiratory infection. Histological characterization of the neoplasm was not possible, as the patient’s family refused an autopsy.

C1qN can present with NS, typically with histological phenotype of either MCD or FSG. In a report of 15 pediatric patients with C1qN, 9 children had corticosteroid-resistant NS. FSG was diagnosed in four cases with poor outcome. Markowitz et al. reported 19 patients with C1qN, 79% of which levels of cyclosporine were 176ng/mL. In an attempt to reduce proteinuria, non-steroidal anti-inflammatory drugs were tried, without response. Cyclosporine was stopped and a right nephrectomy was performed. FSG was noted in all of the 15 glomeruli, with persistence of mesangial C1q deposits. It is plausible that the first biopsy was not representative, or maybe this findings represented the rapid course of the disease.
with nephrotic proteinuria. Renal biopsy disclosed FSG in 17 patients and MCD in two. Four patients with FSG had progressive renal insufficiency and two developed ESRD within 27 months. In a report of 20 pediatric patients, 70% presented nephrotic range proteinuria. The most common histological phenotypes were FSG (40%) and MCD (30%). Patients with FSG had poor prognosis, with half progressing to ESRD in 3 years. In the report of Vizjak et al. comprising 72 kidney biopsies with C1qN, FSG was found in 11 patients with NS, 33% which progressed to ESRD within 2.9 years. Hisano et al. reported a lower prevalence of NS (41%) among 61 Japanese patients with C1qN. The prevalence of MCD in the nephrotic group was 92%, while FSG corresponded only to 8% of the cases. The majority of the patients in nephrotic group were frequent relapsers, but only 4% progressed to ESRD.

A paraneoplastic syndrome is usually inferred when glomerular proteinuria develops in the six months before or after the diagnosis of malignancy. In our patient, initial evaluation didn’t provide any clue to an underlying malignancy. His systemic manifestations were attributed to severe protein loss, as well as to prolonged periods of hospitalization. Five months after the diagnosis of NS, a right pleural effusion persisted after achievement of euvolemia, and a CT was performed showing a disseminated neoplasm. The patient’s clinical condition had markedly deteriorated and he died of sepsis and respiratory failure within a week.

Previous immunosuppressive therapy may have triggered tumor cells, and promote the rapid and inexorable outcome. The patient was a heavy smoker, a known risk factor for several types of neoplasm, including lung and gastrointestinal tract carcinomas, the most frequently associated with paraneoplastic glomerulopathies. He also had high levels of NSE and Ca 19.9, which can be found in gastrointestinal and lung cancers.

Failure to recognize paraneoplastic glomerulonephritis can subject patients to ineffective and potentially harmful therapy. It is important to highlight the possible association between C1qN and malignancy. Before refractory NS associated with C1qN, an underlying malignancy should be suspected.

Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.


Sofia Rocha1, M. João Carvalho1, Luísa Lobato1, Josefina Santos1, Guilherme Rocha2, Ramón Vizcaíno2, António Cabrita1

1 Department of Nephrology. Hospital de Santo António, Centro Hospitalar do Porto. Porto (Portugal).
2 Department of Pathology. Hospital de Santo António, Centro Hospitalar do Porto. Porto (Portugal).

Correspondence: Sofia Rocha
Department of Nephrology, Hospital de Santo António, Centro Hospitalar do Porto. Largo Professor Abel Salazar, 4099-001, Porto, Portugal.
sofia.rocha81@gmail.com
asgr_sigel@hotmail.com